Clinical Study of BCG Vaccine for Intradermal Injection
Condition:   Tuberculosis Interventions:   Biological: BCG vaccine 1(0.025mg/0.1ml/person);   Biological: BCG vaccine 2 (0.05mg/0.1ml/person);   Biological: BCG vaccine 3(0.075mg/0.1ml/person);   Biological: BCG vaccine 4 (0.075mg/0.1ml/person);   Biological: Placebo of BCG vaccine (0.1ml/person) Sponsor:   Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

TB Screening Improves Preventive Therapy Uptake
Conditions:   Tuberculosis;   Latent Tuberculosis;   Tuberculosis Prevention;   HIV Intervention:   Device: CRP, point-of-care assay Sponsors:   University of California, San Francisco;   Makerere University;   Infectious Diseases Research Collaboration, Uganda;   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

TB Screening Improves Preventive Therapy Uptake
Conditions:   Tuberculosis;   Latent Tuberculosis;   Tuberculosis Prevention;   HIV Intervention:   Device: CRP, point-of-care assay Sponsors:   University of California, San Francisco;   Makerere University;   Infectious Diseases Research Collaboration, Uganda;   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

TB Screening Improves Preventive Therapy Uptake
Conditions:   Tuberculosis;   Latent Tuberculosis;   Tuberculosis Prevention;   HIV Intervention:   Device: CRP, point-of-care assay Sponsors:   University of California, San Francisco;   Makerere University;   Infectious Diseases Research Collaboration, Uganda;   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

TB Screening Improves Preventive Therapy Uptake
Conditions:   Tuberculosis;   Latent Tuberculosis;   Tuberculosis Prevention;   HIV Intervention:   Device: CRP, point-of-care assay Sponsors:   University of California, San Francisco;   Makerere University;   Infectious Diseases Research Collaboration, Uganda;   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

TB Screening Improves Preventive Therapy Uptake
Conditions:   Tuberculosis;   Latent Tuberculosis;   Tuberculosis Prevention;   HIV Intervention:   Device: CRP, point-of-care assay Sponsors:   University of California, San Francisco;   Makerere University;   Infectious Diseases Research Collaboration, Uganda;   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

TB Screening Improves Preventive Therapy Uptake
Conditions:   Tuberculosis;   Latent Tuberculosis;   Tuberculosis Prevention;   HIV Intervention:   Device: CRP, point-of-care assay Sponsors:   University of California, San Francisco;   Makerere University;   Infectious Diseases Research Collaboration, Uganda;   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 20, 2020 Category: Research Source Type: clinical trials

TB Screening Improves Preventive Therapy Uptake
Conditions:   Tuberculosis;   Latent Tuberculosis;   Tuberculosis Prevention;   HIV Intervention:   Device: CRP, point-of-care assay Sponsors:   University of California, San Francisco;   Makerere University;   Infectious Diseases Research Collaboration, Uganda;   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 19, 2020 Category: Research Source Type: clinical trials

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
Condition:   Human Immunodeficiency Virus Interventions:   Biological: M72/AS01E Mycobacterium tuberculosis vaccine;   Biological: Placebo Sponsor:   Bill & Melinda Gates Medical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 19, 2020 Category: Research Source Type: clinical trials

Microneedles for Diagnosis of LTBI
Condition:   Latent Tuberculosis Intervention:   Diagnostic Test: TST vs PPD microneedle test Sponsors:   The HIV Netherlands Australia Thailand Research Collaboration;   National Nanotechnology Center (NANOTEC), The National Science and Technology Development Agency (NSTDA) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark
AbstractObjectives: The Bacille Calmette-Gu érin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and mortality have been reported. We aim to test whether BCG vaccination may reduce susceptibility to and/or the severity of COVID- 19 and other infectious diseases in health care workers (HCW) and thus prevent work absenteeism.The primary objective is to reduce absenteeism due to illness among HCW during the COVID-19 pandemic. The secondary objectives are to reduce the number of HCW that are infected with S...
Source: Trials - September 17, 2020 Category: Research Source Type: clinical trials

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions:   Infections and Infestations;   Pulmonary Tuberculosis Interventions:   Drug: Delpazolid;   Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors:   LegoChem Biosciences, Inc;   Ludwig-Maximilians - University of Munich;   Radboud University;   University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions:   Tuberculosis;   Hiv Interventions:   Drug: Rifapentine daily;   Drug: Rifapentine weekly Sponsors:   Yale University;   Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions:   Infections and Infestations;   Pulmonary Tuberculosis Interventions:   Drug: Delpazolid;   Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors:   LegoChem Biosciences, Inc;   Ludwig-Maximilians - University of Munich;   Radboud University;   University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions:   Tuberculosis;   Hiv Interventions:   Drug: Rifapentine daily;   Drug: Rifapentine weekly Sponsors:   Yale University;   Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions:   Infections and Infestations;   Pulmonary Tuberculosis Interventions:   Drug: Delpazolid;   Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors:   LegoChem Biosciences, Inc;   Ludwig-Maximilians - University of Munich;   Radboud University;   University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions:   Tuberculosis;   Hiv Interventions:   Drug: Rifapentine daily;   Drug: Rifapentine weekly Sponsors:   Yale University;   Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions:   Infections and Infestations;   Pulmonary Tuberculosis Interventions:   Drug: Delpazolid;   Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors:   LegoChem Biosciences, Inc;   Ludwig-Maximilians - University of Munich;   Radboud University;   University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions:   Tuberculosis;   Hiv Interventions:   Drug: Rifapentine daily;   Drug: Rifapentine weekly Sponsors:   Yale University;   Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions:   Infections and Infestations;   Pulmonary Tuberculosis Interventions:   Drug: Delpazolid;   Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors:   LegoChem Biosciences, Inc;   Ludwig-Maximilians - University of Munich;   Radboud University;   University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Conditions:   Tuberculosis;   Hiv Interventions:   Drug: Rifapentine daily;   Drug: Rifapentine weekly Sponsors:   Yale University;   Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Conditions:   Infections and Infestations;   Pulmonary Tuberculosis Interventions:   Drug: Delpazolid;   Drug: Bedaquiline, Delamanid, Moxifloxacin Sponsors:   LegoChem Biosciences, Inc;   Ludwig-Maximilians - University of Munich;   Radboud University;   University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2020 Category: Research Source Type: clinical trials

Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon
Condition:   Tuberculosis Intervention:   Drug: TB treatment according to national guidelines Sponsor:   University Hospital, Bonn Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2020 Category: Research Source Type: clinical trials